Navigation Links
Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
Date:1/3/2008

CALGARY, Jan. 3 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the U.S. National Cancer Institute (NCI) has filed a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal or fallopian tube cancers using concurrent systemic and intraperitoneal administration of REOLYSIN(R), Oncolytics' proprietary formulation of the human reovirus. The NCI is sponsoring the trial under its Clinical Trials Agreement with Oncolytics, while Oncolytics will provide clinical supplies of REOLYSIN(R).

The trial, which is being carried out at The Ohio State University Comprehensive Cancer Center, is expected to enroll up to 70 patients with metastatic ovarian, peritoneal or fallopian tube cancers.

These cancer indications were selected after comprehensive preclinical studies carried out by the NCI indicated the reovirus can kill ovarian cancer cells.

The American Cancer Society estimates that more than 22,000 women will be diagnosed with ovarian cancer in the U.S. in 2007, and more than 15,000 will die from it.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.S. NCI Phase I/II systemic and intraperitoneal administr
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... ANNAPOLIS, Maryland , 15. September 2014 /PRNewswire/ ... Week (IPAW) wird vom 12. bis 18. ... der Plasma Protein Therapeutics Association (PPTA) ... Ziele: , Das globale Bewusstsein für ... Den Beitrag von Plasmaspendern beim Retten und Verbessern ...
(Date:9/14/2014)... September 15, 2014 UMBC’s Biotechnology ... on Tuesday, October 21, 2014, from 12:00 to 1:00 ... the program’s innovative curriculum and practice-oriented instruction, designed for ... degree can help advance their career in the biotechnology ... online . , About UMBC’s Biotechnology Graduate Programs, ...
(Date:9/12/2014)... AMSTERDAM , Sept. 12, 2014   Arthur ... startup bio-bean, has won the Postcode Lottery Green Challenge ... awarded Kay euro 500,000 ($680,000 USD) at the final ... green business plan. Kay,s company uses ... advanced biofuel products, namely biodiesel and biomass pellets, used ...
(Date:9/12/2014)... 12, 2014 Sandia Biotech, Inc. announced ... agreement with STC.UNM (STC) for a technology developed by ... Albuquerque, New Mexico, and Queen Mary University of London ... the Recombinant Fluorescent Antibody Technology Platform (RFAP) was developed ... Medicine and Dr. Angray Kang from Queen Mary’s Department ...
Breaking Biology Technology:International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 3Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 2Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 3Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 4
... Corporation,s (Amex: ETC ) ("ETC" or the ... two (2) BARA-MED(R),Monoplace Hyperbaric Chambers at East Orange ... is a fully accredited, acute care hospital,located in ... of East Orange,General Hospital is run by Dr. ...
... of Enrollment in U.S. Phase II Study,of Nitazoxanide ... TAMPA, Fla., Oct. 28 Romark Laboratories, ... of studies,of nitazoxanide at the upcoming 59th Annual ... Liver Diseases (AASLD), also known as The,Liver Meeting(R), ...
... N.J., Oct. 28 BioWa, Inc. announced ... with KaloBios Pharmaceuticals, Inc.,under which BioWa licenses ... antibody-dependent cellular cytotoxicity (ADDC) of select,KaloBios therapeutic ... strategic partnership with KaloBios,",commented Dr. Masamichi Koike, ...
Cached Biology Technology:Environmental Tectonics Corporation's BioMedical Systems Division Places Two Monoplace Chambers at East Orange (NJ) General Hospital 2Environmental Tectonics Corporation's BioMedical Systems Division Places Two Monoplace Chambers at East Orange (NJ) General Hospital 3Environmental Tectonics Corporation's BioMedical Systems Division Places Two Monoplace Chambers at East Orange (NJ) General Hospital 4Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco 2BioWa Announces License of Biowa's Potelligent(R) Technology to KaloBios Pharmaceuticals 2
(Date:9/15/2014)... wild, domesticated, and domesticated-wild hybridized populations of ... that within 5 to 11 generations, selection ... populations that hybridized with domesticated populations. , ... evidence that natural selection, over time, removes ... as a result of increased genetic diversity. ...
(Date:9/15/2014)... Ebola virus outbreak in West Africa, which has claimed ... a deeper understanding of the molecular biology of the ... vaccines or antiviral drugs to treat or prevent Ebola ... Virginia (UVA), USA under the leadership of Dr ... structural biologist has obtained the crystal structure of ...
(Date:9/15/2014)... cardiovascular disease (CVD) claims 17 million lives each year, ... 9.4 million. 1 New research presented by international ... Montpellier, France on September 15, 2014, suggests that milk ... , At the Milk and Dairy Products in ... risk for hypertension and CVD was examined by Dr. ...
Breaking Biology News(10 mins):Protein secrets of Ebola virus 2Dairy consumption linked to lower blood pressure and cardiovascular disease risk 2
... join the two copies of each chromosomecalled sister chromatidsto ... cells during cell division. In this way, each daughter ... parent cell. Pds5 is a protein associated with ... vertebrates there are two variants of Pds5, Pds5A and ...
... industrial cities is often an overlooked resource. Years of manufacturing ... and scare residents away from using the land. As the ... the desire to grow food in cities with the fear ... at 10:35 am, Kristen McIvor of the Pierce Conservation District ...
... Zhang, a biochemist and geneticist with Texas A&M AgriLife ... million from the National Science Foundation to further his ... ultimately could help breed more productive plants. The ... is given in "support of junior faculty who exemplify ...
Cached Biology News:CNIO researchers delve into the behavior of cohesins 2Fostering community gardens in an area with historic soil contamination 2AgriLife researcher Xiuren Zhang receives National Science Foundation CAREER grant 2
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
...
...
...
Biology Products: